Surrozen

Surrozen is a clinical-stage biotechnology company developing targeted antibodies that selectively modulate Wnt signalling, the pathway that governs stem-cell renewal, tissue structure and repair, with its current focus on sight-threatening ophthalmic disease. Its lead candidate, SZN-8141, is a bifunctional antibody that combines Frizzled 4 (FZD4)-mediated Wnt agonism with VEGF antagonism to address both vascular leakage and retinal vascular integrity; the company submitted an Investigational New Drug application for SZN-8141 in diabetic macular edema in September 2026 and expects to begin the DUET Phase 1b/2a study by year-end 2026, with initial data anticipated in the second half of 2027. The earlier SZN-043 programme, built on the company's SWEETS technology, is a Wnt agonist antibody developed for severe liver disease, initially severe alcohol-associated hepatitis, and has completed a Phase 1a study in chronic liver disease and healthy volunteers ahead of a Phase 1b multiple-ascending-dose trial.